trending Market Intelligence /marketintelligence/en/news-insights/trending/eKqLcWSLQ3S0uh8rHK88AA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Dechra Pharmaceuticals adds director

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Dechra Pharmaceuticals adds director

Dechra Pharmaceuticals PLC appointed Lisa Bright to the board as a nonexecutive director, effective Feb. 1, 2019.

Bright serves on the board of Ascendis Pharma A/S and has been president, international, at Intercept Pharmaceuticals Inc. since July 2016. She was also previously a vice president at GlaxoSmithKline PLC and Gilead Sciences Inc.

Northwich, U.K.-based Dechra Pharmaceuticals develops veterinary pharmaceuticals and related products for veterinarians worldwide.